ReviewCancer chemotherapy and pharmacology1994
Pharmacodynamics and long-term toxicity of etoposide.
Review in Cancer chemotherapy and pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 60 citations in OpenAlex.
- Model-informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records.British journal of clinical pharmacology · 2026Article
- The Microbial Metabolite IDA Sensitizes Tumor Cells to ARF1 Inhibition by Inducing SVIL-dependent Senescence.International journal of biological sciences · 2026Article
- Development of New Pyrazolo [3,4-Pharmaceuticals (Basel, Switzerland) · 2025Article
- Organo NHC catalyzed aqueous synthesis of 4β-isoxazole-podophyllotoxins:RSC advances · 2024Article
- Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy.Biologics : targets & therapy · 2024Review
- Transcriptional patterns reveal tumor histologic heterogeneity and immunotherapy response in lung adenocarcinoma.Frontiers in immunology · 2022Article
- Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC).International journal of environmental research and public health · 2020Article
- Metformin as a protective agent against natural or chemical toxicities: a comprehensive review on drug repositioning.Journal of endocrinological investigation · 2020Review
- Radiosensitization of Head and Neck Squamous Cell Carcinoma (HNSCC) by a Podophyllotoxin.ACS medicinal chemistry letters · 2019Article
- Article
- Inhibition of Topoisomerase IIα and Induction of Apoptosis in Gastric Cancer Cells by 19-Triisopropyl AndrographolideAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Click chemistry-assisted synthesis of triazolo linked podophyllotoxin conjugates as tubulin polymerization inhibitors.MedChemComm · 2017Article
- Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro.Toxicology in vitro : an international journal published in association with BIBRA · 2012Article
- A novel topoisomerase inhibitor, daurinol, suppresses growth of HCT116 cells with low hematological toxicity compared to etoposide.Neoplasia (New York, N.Y.) · 2011Article
- Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan.Medical oncology (Northwood, London, England) · 2010Article
- Population pharmacokinetic studies in pediatrics: issues in design and analysis.The AAPS journal · 2005Review
- Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.Journal of pharmacokinetics and pharmacodynamics · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Etoposide has been used in the treatment of a wide variety of neoplasms, including small-cell lung cancer, Kaposi's sarcoma, testicular cancer, acute leukemia, and lymphoma. Its current therapeutic use is limited by myelosuppression, particularly neutropenia. Pharmacodynamic studies of etoposide show that this toxicity can be modeled using a modified Hill equation and that the dose intensity of etoposide can be successfully increased by adaptive control using this model. Significant influences on the degree of myelosuppression include the pretreatment leukocyte count, the performance status, the extent of prior erythrocyte transfusions, and the serum albumin level. In the past 7 years, interest has developed in a distinct subset of acute nonlymphocytic leukemia that is associated with prior exposure to etoposide. This syndrome has been described in several studies and is characterized by the lack of a preleukemic phase, M4 or M5 morphology, and distinct translocations involving the chromosome 11q23 region. In addition, secondary acute lymphocytic leukemias (involving 11q23) have also been associated with prior epipodophyllotoxin exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.